UPDATE: Morgan Stanley Raises Target to $48 on CVS Caremark

CVS raises its price target on CVS Caremark

to $48 ahead of guidance from the company on outlook. Morgan Stanley says, "Retail share gains and execution on PBM front gets us closer to our bull case. CVS guidance implies capturing ~26% to 30% of WAG's lost ESRX retail scripts, by our estimates. We are raising our CY12 EPS to $3.29 (from $3.25), ahead of guidance mid-point of $3.23." CVS closed at $43.57 a share yesterday.